Press Releases NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Market Closed - Toronto S.E. Other stock markets 03:59:59 2024-05-03 pm EDT			5-day change	1st Jan Change
2.33 ^CAD	+7.87%		+10.43%	-13.70%

Apr. 17	NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update	MT
Apr. 17	NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NervGen Engages Russo Partners LLC to Provide Public Relations Services	Apr. 25	NE
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates	Apr. 17	NE
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off	Apr. 09	AQ
NervGen Completes $23 Million Bought Deal Financing	Mar. 28	NE
Canadian Investment Regulatory Organization Trade Resumption - NGEN	Mar. 21	AQ
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING	Mar. 21	AQ
Canadian Investment Regulatory Organization Trading Halt - NGEN	Mar. 21	AQ
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company	Feb. 21	NE
NervGen Pharma Grants Stock Options	Feb. 20	NE
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury	Feb. 15	NE
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates	Nov. 09	NE
Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy Kawasaki	Nov. 08	NE
NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury	23-10-23	NE
NervGen Pharma Appoints John Ruffolo to Board of Directors	23-10-17	NE
NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury	23-09-25	NE
NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting	23-09-12	AQ
NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conference	23-09-06	AQ
NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at Investor Conference	23-08-23	AQ
NervGen Pharma Reports Q2 2023 Financial Results and Operational Updates	23-08-10	AQ
NervGen Pharma to Proceed With Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval	23-08-09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Press Releases

Filters